This is a routine cross-listing compliance filing. Ignore for trading purposes — the relevant financial data was already disclosed in the August 5 earnings release. Monitor the next catalyst: Phase 3 MANGROVE data and regulatory submissions for BRUKINSA in first-line MCL expected in 2H 2026.
Price Chart
Executive Summary
BeOne Medicines filed its STAR Market interim report (H1 2026) in China, disclosing R&D spending breakdown by key product in accordance with PRC GAAP. The filing is a routine dual-listing disclosure requirement, not a standalone earnings release. It provides incremental transparency on pipeline investment allocation but contains no new financial results or guidance beyond what was released in the Q2 2026 earnings report on August 5, 2026.
Key Facts
- Filed PRC GAAP-based interim report with Shanghai Stock Exchange STAR Market for H1 2026
- Disclosed R&D expenses allocated by key products: BEQALZI ($74M), tacabrutideg ($44M), BRUKINSA ($43M), TEVIMBRA ($37M), BGB-43395 ($23M)
- Total U.S. GAAP R&D spend for H1 2026: $1.15B (vs $1.01B in H1 2025)
- Material accounting differences between PRC GAAP and U.S. GAAP on share-based compensation, income taxes, and leasing
- No new financial results, guidance, or business updates beyond August 5, 2026 earnings
Financial Impact
No material financial impact — this is a disclosure compliance filing with no new economic data
Risk Factors
- No new information risk — stock should not move on this filing
- Potential confusion if market misreads as a separate earnings release
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001651308-26-000025 |
| Document: 0001651308-26-000025-index.html | 0001651308-26-000025 |
| Document: 0001651308-26-000025.txt | 0001651308-26-000025 |
| 8-K Data (Synthetic) | 0001651308-26-000025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Insider Cluster | $346.51 $350.84 | ▲ +1.25% | ▲ +1.47% | $358.07 (+3.34%) |
Sep 3, 2026 29d ago | Insider Cluster | $362.68 $346.51 | ▼ −4.46% | ▼ −3.31% | $358.07 (−1.27%) |
Aug 26, 2026 5w ago | 8-K | $375.80 $361.78 | ▼ −3.73% | ▼ −3.61% | $358.07 (−4.72%) |
Aug 14, 2026 7w ago | Insider Cluster | $347.48 $374.47 | ▲ +7.77% | ▲ +9.14% | $358.07 (+3.05%) |
Aug 12, 2026 7w ago | Insider Cluster | $356.01 $369.16 | ▲ +3.69% | ▲ +5.66% | $358.07 (+0.58%) |
Aug 10, 2026 7w ago | 144 | $359.27 $369.15 | ▼ −2.75% | ▼ −3.15% | $358.07 (+0.33%) |
Aug 5, 2026 8w ago | Insider Cluster | $329.80 $356.01 | ▲ +7.95% | ▲ +6.73% | $358.07 (+8.57%) |
Aug 5, 2026 8w ago | 8-K | $327.53 $359.05 | ▲ +9.62% | ▲ +9.27% | $358.07 (+9.32%) |
Jul 24, 2026 10w ago | Insider Cluster | $325.90 $322.08 | ▼ −1.17% | ▼ −1.55% | $358.07 (+9.87%) |
Jul 17, 2026 11w ago | Insider Cluster | $312.02 $326.77 | ▼ −4.73% | ▼ −5.41% | $358.07 (−14.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access